Effects of individual shock wave therapy vs celecoxib on hip pain caused by femoral head necrosis

Table 1 Patient characteristics, mean ± SD

Characteristic	Group A	Group B	P value
Patients, n	35	35
Sex, male/female	26/10	18/17
Age in yr	40.06 ± 13.48	43.72 ± 13.69	0.2561
Weight in kg	71.82 ± 11.02	67.79 ± 10.93	0.1241
Height in cm	171.6 ± 7.71	168.4 ± 8.22	0.0991
BMI in kg/m2	24.4 ± 3.59	23.8 ± 2.85	0.4241
Pain duration in mo	14.8 ± 7.99	13.7 ± 7.89	0.5641

¹Paired-samples t-test data are expressed as mean ± SD or n (%).

Data were analyzed using unpaired t-test. BMI: Body mass index.

Table 2 Outcome assessment before and after treatment

Parameter	Baseline	1 d	2 wk	4 wk	8 wk
Group A
Patients, n	35	35	35	35	35
HHS range 0-100, mean ± SD	51.8 ± 11.8	51.8 ± 11.6	57.9 ± 12.5	52.9 ± 11.5	52.7 ± 11.2
Difference vs baseline		0.9621	< 0.0011	0.2181	0.3151
Difference vs group B		< 0.0012	0.0042	0.0472	0.1472
VAS (0-10), mean ± SD	5.3 ± 1.1	5.0 ± 1.0	3.9 ± 1.0	4.1 ± 1.0	4.4 ± 1.0
Difference vs baseline		0.0031	< 0.0011	< 0.0011	< 0.0011
Difference vs group B		< 0.0012	< 0.0012	0.2572	0.1662
WOMAC range 0-240, mean ± SD	93.7 ± 32.4	92.3 ± 31.8	87.6 ± 31.5	89.3 ± 31.4	90.2 ± 31.2
Difference vs baseline		0.0221	< 0.0011	< 0.0011	< 0.0011
Difference vs group B		0.1962	0.4472	0.5962	0.6512
Group B
Patients, n	35	35	35	35	35
HHS range 0-100, mean ± SD	53.9 ± 13.3	62.4 ± 11.6	62.9 ± 12.1	58.5 ± 12.0	56.9 ± 12.9
Difference vs baseline		< 0.0011	< 0.0011	< 0.0011	< 0.0011
VAS range 0-10, mean ± SD	5.0 ± 1.2	3.1 ± 1.1	3.0 ± 1.0	3.9 ± 1.1	4.1 ± 1.1
Difference vs baseline		< 0.0011	< 0.0011	< 0.0011	< 0.0011
WOMAC range 0-240, mean ± SD	91.0 ± 25.1	83.5 ± 23.9	82.5 ± 24.0	86.0 ± 24.3	87.1 ± 24.7
Difference vs baseline		< 0.0011	< 0.0011	< 0.0011	< 0.0011

¹Paired-sample t-test.

²Two-sample independent t-test statistical significance at P < 0.05.

HHS: Harris hip score; VAS: Visual analog scale; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index.